{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:09:56Z","timestamp":1792602596234,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a relapsing and remitting skin disease often requiring long\u2010term treatment. Tralokinumab, a monoclonal antibody specifically neutralizing interleukin\u201013, is approved for moderate\u2010to\u2010severe AD treatment in multiple countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Assess long\u2010term efficacy of tralokinumab in adults with moderate\u2010to\u2010severe AD treated for up to 4\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This post hoc interim analysis included the subgroup of patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009347) who completed 52\u2009weeks of tralokinumab in the Phase 3 ECZTRA 1 or ECZTRA 2 (NCT03131648\/NCT03160885) trials and subsequently enrolled in the open\u2010label extension trial ECZTEND (NCT03587805; receiving tralokinumab plus optional topical corticosteroids\/calcineurin inhibitors [TCS\/TCI]) \u2265152\u2009weeks prior to data cut\u2010off (30\u2010April\u20102022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At ECZTEND Week 152, 52.6% (95% CI 45.2; 59.8) of patients achieved Investigator's Global Assessment 0\/1 (clear or almost clear skin) and 84.5% (95% CI 78.4; 89.1) achieved \u226575% improvement in Eczema Area and Severity Index (EASI) from parent trial baseline; additionally, 84.5% (95% CI 78.4; 89.1), 68.0% (95% CI 60.8; 74.5) and 79.0% (95% CI 72.1; 84.6) reached EASI \u22647 (no\u2010to\u2010mild disease), Worst Weekly Pruritus Numeric Rating Scale \u22644 (no\u2010to\u2010mild itch) and Dermatology Life Quality Index \u22645 (no\u2010to\u2010small effect on quality of life), respectively. Responses were stable over time, with 71.4% (95% CI 66.3; 76.0) of patients maintaining EASI \u22647 at \u226580% of days between Week 16 and 152 in ECZTEND. During ECZTEND, 28.5% of patients discontinued: 7.5% due to lack of efficacy and 5.8% due to adverse events (AEs). The most frequently reported AEs in ECZTEND were consistent with the known safety profile of tralokinumab, including nasopharyngitis (IR\u2009=\u200913.6), upper respiratory tract infection (IR\u2009=\u20094.4) and conjunctivitis (IR\u2009=\u20092.3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data suggest that tralokinumab plus optional TCS\/TCI provides long\u2010term stable disease control, equivalent to no\u2010to\u2010mild disease, in a subgroup of adults with moderate\u2010to\u2010severe AD who completed 1\u2009year of treatment in parent trials and up to 3\u2009years in ECZTEND.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70165","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:18:06Z","timestamp":1762867086000},"page":"876-886","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of up to 4\u2009years of tralokinumab in adults with moderate\u2010to\u2010severe atopic dermatitis"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda","family":"Gooderham","sequence":"first","affiliation":[{"name":"SKiN Centre for Dermatology  Peterborough Ontario Canada"},{"name":"Department of Medicine Queen's University  Kingston Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahreen","family":"Ameen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Royal Free London National Health Services Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih\u2010ho","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[{"name":"Dr. Chih\u2010ho Hong Medical Inc.  Surrey British Columbia Canada"},{"name":"North Campus Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[{"name":"Division of Clinical Dermatology and Cutaneous Science Dalhousie University  Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-6600","authenticated-orcid":false,"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Dermatology Catholic University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-4332","authenticated-orcid":false,"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-6338","authenticated-orcid":false,"given":"Juan F.","family":"Silvestre","sequence":"additional","affiliation":[{"name":"Dermatology Department Hospital General Universitario Dr Balmis, ISABIAL  Alicante Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Oregon Health &amp; Science University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Hannover Medical School  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Gjerum","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S  Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann\u2010Marie","family":"Tindberg","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S  Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Bjerreg\u00e5rd","family":"\u00d8land","sequence":"additional","affiliation":[{"name":"Previously LEO Pharma A\/S  Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Blauvelt Consulting, LLC  Annapolis Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3511"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00631-8"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03130-w"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.102"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18345"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15811"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00702-2"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00806-3"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.019"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf309"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3751"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.01.053"},{"key":"e_1_2_13_17_1","unstructured":"ADBRY\u00ae (tralokinumab\u2010Idrm) injection for subcutaneous use [prescribing information]. LEO Pharma A\/S Ballerup DK 2023."},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21867"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00897-0"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16108"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0183-2021"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076316","article-title":"The estimands framework: a primer on the ICH E9(R1) addendum","volume":"384","author":"Kahan BC","year":"2024","journal-title":"BMJ"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12561-021-09301-x"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280210394469"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:25:06Z","timestamp":1777533906000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/jdv.70165"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70165","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"2025-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}